Company & Sponsor Intelligence
ACADIA Pharmaceuticals Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials2
Recruiting0
Completed2
Countries1
Therapeutic footprint
parkinsons
Indexed studies
NCT01174004A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
parkinsons · United StatesPHASE3
parkinsons · United StatesPHASE3
NCT03482882Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression
parkinsons · United StatesPHASE2
parkinsons · United StatesPHASE2
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →